Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases.
Bioactive peptides like Semax may have potential neuroprotective roles in neurodegenerative diseases, but more clinical validation is needed.
Where it sits
this study against the rest of the semax corpusSummary and findings
This review examines the neuroprotective roles of bioactive peptides and proteins/polypeptides in neurodegenerative disorders (NDDs), focusing on their mechanisms of action and potential therapeutic applications. It discusses various peptides, including Semax, and their effects on oxidative stress and neuroinflammation. No specific numeric findings are reported in the abstract.
Abstract
Neurodegenerative disorders (NDDs) pose a growing global health burden, primarily due to their progressive nature and the limited efficacy of existing treatments. Bioactive peptides and proteins/polypeptides, particularly those derived from dietary and natural sources, show promise in modulating neurobiological pathways central to neurodegeneration. This review aims to critically examine the neuroprotective roles of Bioactive peptides and proteins/polypeptides in NDDs, elucidating their mechanisms of action, potential therapeutic applications in conditions like Alzheimer's, Parkinso's disease, Huntington's disease, and others, as well as the trends in peptide-based therapeutics. Bioactive peptides and proteins/polyspeptides, such as NGF, BDNF, GDNF, Semax, and Exendin-4, have been found to modulate several critical mechanisms, including the reduction of oxidative stress (OS), inhibition of neuroinflammation, preservation of mitochondria, and enhancement of synaptic plasticity. These peptides have demonstrated efficacy in preclinical and early-phase clinical trials across a spectrum of NDDs. Delivery challenges, such as blood-brain barrier (BBB) permeability and enzymatic degradation, have been acknowledged. Ongoing innovations in peptide engineering, nanoparticle-based delivery systems, CRISPR-assisted design, and AI-driven screening are addressing these limitations. By targeting multiple pathogenic mechanisms simultaneously, peptide-based therapeutics present a rational and innovative approach to NDD management. Their multifunctional action profiles and ability to target specific molecular pathways highlight their potential as next-generation neuroprotective agents. However, future clinical validation and advanced strategies are essential for translating these promising molecules into effective treatments.
Background
The paper addresses the role of bioactive peptides in modulating neuropathological pathways, particularly in the context of oxidative stress associated with neurodegenerative diseases. Prior research has indicated that oxidative stress is a significant factor in the progression of these conditions, and peptides like Semax may offer new avenues for intervention. This study is relevant as it explores the potential mechanisms through which Semax could exert effects on neurodegenerative pathology.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.